DDInter1643 DDInter1376
Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe rheumatoid arthritis (RA) in combination with methotrexate. RA is a chronic inflammatory disease characterized by polyarthritis, and its treatment has been challenged by the different responses in every patient. Subcutaneous administration of sarilumab has been shown to decrease acute-phase reactant levels and improve clinical RA symptoms.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Sarilumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Sarilumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naltrexone
Sarilumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Sarilumab {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Sarilumab {u} may lead to a major life threatening interaction when taken with {v} Smallpox (Vaccinia) Vaccine, Live
Sarilumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Sarilumab may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone
Sarilumab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Sarilumab may lead to a major life threatening interaction when taken with Cladribine
Sarilumab may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live